Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial

Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial

Abstract Background Mitomycin (MMC) has been frequently used as the compound for intravesical treatment. The relatively new pyrimidine analog gemcitabine (GEM) has exhibited anticancer effect on various solid cancers, such as the advanced bladder cancer. In this study, the GEM and MMC in treating no...

Full description

Bibliographic Details
Main Authors: Rongxin Li, Ye Li, Jun Song, Ke Gao, Kangning Chen, Xiaogang Yang, Yongqiang Ding, Xinlong Ma, Yang Wang, Weipeng Li, Yanan Wang, Zhiping Wang, Zhilong Dong
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Urology
Subjects:
Bladder cancer
Gemcitabine
Mitomycin
Systematic evaluation
Meta-analysis
Online Access:http://link.springer.com/article/10.1186/s12894-020-00610-9

Internet

http://link.springer.com/article/10.1186/s12894-020-00610-9

Similar Items